NLRP3: A Novel Mediator in Cardiovascular Disease.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hyperhomocysteinemia 1 endocrinologydiseases
rosuvastatin 5 endocrinologydiseasesdrugs
atorvastatin 3 endocrinologydiseasesdrugs
glyburide 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
atorvastatin 24041 [[51]]. Moreover, in a randomized clinical trial, patients with coronary artery disease were administered atorvastatin or rosuvastatin for 8 months. Results showed that the expression level of the NLRP3 inflammasome was
atorvastatin 24168 rosuvastatin for 8 months. Results showed that the expression level of the NLRP3 inflammasome was lower in the atorvastatin than in the rosuvastatin group. Such effects might be implicated in the slower progression of atherosclerosis
atorvastatin 28386 the expression level of the NLRP3 inflammasome and slowed the progression of atherosclerosis in the atorvastatin , but not the rosuvastatin, group[[52]]Patients with ST-elevation MIColchicineReduced the infarct size[[59]]Patients
glyburide 22550 lipopolysaccharide (LPS) and in a sepsis mouse model [[47]]. Inhibition of the NLRP3 inflammasome by using glyburide could ameliorate myocardiac dysfunction induced by sepsis [[47]]. In the background of sepsis, Xie et
rosuvastatin 24057 randomized clinical trial, patients with coronary artery disease were administered atorvastatin or rosuvastatin for 8 months. Results showed that the expression level of the NLRP3 inflammasome was lower in the atorvastatin
rosuvastatin 24193 showed that the expression level of the NLRP3 inflammasome was lower in the atorvastatin than in the rosuvastatin group. Such effects might be implicated in the slower progression of atherosclerosis [[52]]. Interestingly,
rosuvastatin 24314 Such effects might be implicated in the slower progression of atherosclerosis [[52]]. Interestingly, rosuvastatin , on the other hand, was proven to be potent in the treatment of DCM by inhibiting the NLRP3 inflammasome
rosuvastatin 28253 and thus mtROS accumulation[[56]]Clinical trialsPatients with coronary artery diseaseAtorvastatin or rosuvastatin for 8 monthsReduced the expression level of the NLRP3 inflammasome and slowed the progression of atherosclerosis
rosuvastatin 28412 the NLRP3 inflammasome and slowed the progression of atherosclerosis in the atorvastatin, but not the rosuvastatin , group[[52]]Patients with ST-elevation MIColchicineReduced the infarct size[[59]]Patients with coronary
Select Disease Character Offset Disease Term Instance
hyperhomocysteinemia 12287 mice with Apoe deficiency alone, Apoe−/− mice fed with a high-fat diet and high-methionine diet (a hyperhomocysteinemia - (HHcy-) induced atherosclerosis model) showed an increased atherosclerotic plaque size. Silencing NLRP3

You must be authorized to submit a review.